Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026

An article published recently on the Expert Review of Medicine reviews the epidemiology of obesity and its impact on pulmonary arterial hypertension. The typical patient has changed over the years from a young, lean, woman to an older person with other conditions such as obesity, diabetes or heart disease. Obesity is now one of the […]

Pulmonary arterial hypertension (PAH) in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026 Read Post »

First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026

Researchers from a tertiary pulmonary hypertension expert center in Abu Dhabi, United Arab Emirates, conducted a retrospective single-center cohort study (PH RISE-ME) evaluating the real-world effectiveness and safety of sotatercept in adults with pulmonary arterial hypertension already on optimised background therapy. The findings reveal that adding sotatercept In this cohort was associated with improved right-heart

First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026 Read Post »

Impaired BMPR2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026

A multicentre German study, run at specialist centres in Heidelberg, Hannover and Giessen/Marburg, looked at the key gene in pulmonary hypertension, BMPR2. Changes in this gene cause most inherited cases of pulmonary arterial hypertension, and the biological pathway it controls is also the target of sotatercept. The researchers took blood samples from 234 people in

Impaired BMPR2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026 Read Post »

Researchers at Brown University, USA, find that molecular profiles may help create more effective individualized treatment for pulmonary arterial hypertension, The Brown Daily Herald, October 15, 2026

In a retrospective study, researchers at Brown University looked back at data from patients with pulmonary arterial hypertension. Their cells had been collected from the lung blood vessels during routine catheter procedures. After they collected the cells, the researchers sequenced the cells’ RNA content. Next, they used a bioinformatics pipeline to determine which specific molecular

Researchers at Brown University, USA, find that molecular profiles may help create more effective individualized treatment for pulmonary arterial hypertension, The Brown Daily Herald, October 15, 2026 Read Post »

Sotatercept in Paediatric Pulmonary Hypertension: Experience from the Pediatric Pulmonary Hypertension Network, CHEST Journal, October 5, 2026

Despite robust evidence in adult patients, up to now there was limited data on the use of sotatercept in pediatric pulmonary hypertension patients. The findings of a multi-center, retrospective study of children and young adults ≤ 21 years of age with paediatric pulmonary hypertension, treated by programs in the Pediatric Pulmonary hypertension Network (PPHNet) and

Sotatercept in Paediatric Pulmonary Hypertension: Experience from the Pediatric Pulmonary Hypertension Network, CHEST Journal, October 5, 2026 Read Post »

Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real-World US Claims Data Analysis, Pulmonary Circulation, October 6, 2026

A study using United States insurance claims data looked at the real-world burden of pulmonary arterial hypertension in 2,712 treated adults between 2017 and 2024 (average age 62, 69% women). Over an average follow-up of just over two years: The authors conclude that, despite recent advances in treatment, the disease still carries a heavy clinical

Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real-World US Claims Data Analysis, Pulmonary Circulation, October 6, 2026 Read Post »

Every Breath Counts: The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), European Medical Journal, October 20, 2026

This article contains an abstract and full transcript of a symposium which took place on 6th September 2026, as part of the European Respiratory Society (ERS) Congress held in Barcelona, Spain, sponsored by INSMED. The Chairperson was Professor Jean-Luc Vachiery and the speakers were Professors Irene Lang (Medical University, Vienna, Austria) Hossein Ardeschir Ghofrani (Giessen

Every Breath Counts: The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension linked to interstitial lung disease (PH-ILD), European Medical Journal, October 20, 2026 Read Post »

Estimating mean pulmonary arterial pressure (mPAP) in the machine learning era, European Respiratory Journal, October 9, 2026

Accurate assessment of mean pulmonary arterial pressure (mPAP) is key to the diagnosis, haemodynamic classification and follow-up of pulmonary hypertension. The article, authored by French researcher at Le Kremlin-Bicêtre, France, requires permissions in order to access the full text, so we are only able to use the shareable abstract which reads “Large real-world datasets analysed

Estimating mean pulmonary arterial pressure (mPAP) in the machine learning era, European Respiratory Journal, October 9, 2026 Read Post »

Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review, Cureus, October 18, 2026

Reaching and keeping low-risk status is now the main treatment goal in pulmonary arterial hypertension, but the evidence on which treatments help patients get there is spread across many studies using different risk tools. A systematic review was conducted by researchers in the UK following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review, Cureus, October 18, 2026 Read Post »

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026

A study published in Journal of Heart and Lung Transplant Open by a large French team looked at all 241 patients with pulmonary arterial hypertension who had a lung or heart-lung transplant in France between 2008 and 2023. Using data from the national registries for the disease and for transplants, the authors compared two periods:

Evolving profile and outcomes of patients with pulmonary arterial hypertension (PAH) undergoing lung transplantation in France, Journal of Heart and Lung Transplant, September 3, 2026 Read Post »

Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026

A prospective, randomised, controlled single-centre study looking at whether fluid restriction (FR) helps pulmonary arterial hypertension patients with right heart failure and signs of volume overload. 41 patients (average age 70, mostly World Health Organisation (WHO) Functional class III, were split between intensified fluid restriction counselling (around 1.5 litres per day) and routine fluid restriction

Randomised, controlled trial on fluid restriction in pulmonary arterial hypertension, Respiration, September 9, 2026 Read Post »

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026

The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) were presented today at the ERS Congress! The Alliance for Pulmonary Hypertension Vice President Louise Bouman – van der Waal was at the congress and attended this important session. Here is the link to the article: https://lnkd.in/evX7wHhe Pisana Ferrari, President of

Breaking news! The European Respiratory Society (ERS) Clinical Practice Guidelines update for Pulmonary Arterial Hypertension (PAH) presented today at the ERS Congress in Barcelona, September 7, 2026 Read Post »

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026

Some patients with pulmonary arterial hypertension experience difficulties with memory, thinking, or mood. A group of Chinese researchers have investigated whether reduced blood flow to the brain is connected to heart strain and disease severity. They compared brain scans from 30 people with pulmonary arterial hypertension and 51 healthy individuals matched for age and sex.

Reduced brain blood flow, heart strain, and cognitive symptoms in pulmonary arterial hypertension, Therapeutic Advances in Respiratory Diseases, Jan-Dec 2026 Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026

The findings of a multi-center randomized controlled trial investigating the long-term efficiency of rehabilitation in patients with pulmonary arterial hypertension was published in the Annals of the American Thoracic Society on July 20, 2026. The study followed 47 patients with stable pulmonary arterial hypertension across 9 French centers, looking at the long-term impact of a

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026 Read Post »

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026

In a recent LinkedIn post Prof. Werner Seeger writes that the GoDeep meta-registry analysis about the predictive power of pulmonary artery stiffness – right ventricular interplay in mild pulmonary hypertension (PH) is now online. He reports that in the analysis, notably, parameters integrating pulsatile vascular load and interdependent right ventricular function possess predictive power independent

Predictive Power of Pulmonary Artery Stiffness – Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026 Read Post »

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026

A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same disturbance shows up in other

Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026 Read Post »

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the French FONCE-HTAP randomized controlled trial, Annals of American Thoracic Society, July 20, 2026

A French multicenter trial (9 centers, 2015–2022) tested whether a 3-month supervised rehabilitation program improves 12-month exercise capacity in pulmonary arterial hypertension patients, using a Zelen design to limit performance bias — addressing a gap left by prior short-term, open-label studies. Key findings: Conclusion: A 3-month supervised rehabilitation program produced a durable, significant improvement in

Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the French FONCE-HTAP randomized controlled trial, Annals of American Thoracic Society, July 20, 2026 Read Post »

Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review via the Pulmonary Vascular Research Institute (PVRI), Pulmonary Circulation, July 14, 2026

A review recently published in Pulmonary Circulation brings together academic and industry researchers (via the PVRI Innovative Drug Discovery Initiative) to consolidate current knowledge on activin signaling inhibitors (ASIs), the role of specific Bone morphogenetic protein (BMP) ligands, efficacy/safety data, and considerations for developing next-generation activin signaling inhibitors. Key points: Open questions remain about: the

Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review via the Pulmonary Vascular Research Institute (PVRI), Pulmonary Circulation, July 14, 2026 Read Post »

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026

In pulmonary arterial hypertension there are significant disparities in epidemiology, clinical outcomes, and healthcare access that disproportionately affect historically neglected populations, including Black Americans, Hispanic Americans, and American Indians. A State-of-the-Art review recently published on CHEST examines the disparities in the three groups. Key points: Conclusion: These disparities stem from structural/socioeconomic barriers and discrimination—not biological differences.

Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026 Read Post »

TRANSLATE »
Scroll to Top